Seroquel (quetiapine) is not approved by the FDA for panic disorder, and the most direct clinical trial testing it for that purpose found it was no better than a placebo. Despite this, quetiapine remains one of the most commonly prescribed off-label antipsychotics for anxiety-related conditions, which means many people with panic attacks end up taking it based on clinical intuition rather than strong trial evidence. The gap between how often it is prescribed and how well it is supported for panic specifically is worth understanding before you fill that prescription.
What the Trial Evidence Says About Panic Disorder
The most relevant study is a randomized, controlled proof-of-concept trial that tested whether adding quetiapine XR (the extended-release form) to an SSRI could help people whose panic disorder had not responded to the SSRI alone. Over eight weeks, both groups improved, but the group receiving quetiapine did not improve more than the group receiving a placebo add-on. The researchers concluded that the strategy was not supported for SSRI-resistant panic disorder.1PubMed Central. A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder A separate review of panic disorder clinical trials from 2010 to 2018 confirmed this finding, noting plainly that quetiapine XR was not superior to placebo.2PubMed Central. Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018
This is a thin evidence base, and that matters. The trial was small and designed as a proof-of-concept, meaning it was an early test to see if a larger study would be worthwhile. The answer it returned was essentially “no.” For comparison, SSRIs and SNRIs have been tested in multiple large trials for panic disorder, which is why they are first-line treatments. Quetiapine simply has not cleared even the preliminary hurdle for this specific condition.
Why Doctors Still Prescribe It for Anxiety
If the evidence is this weak for panic disorder, why do so many people end up on quetiapine for anxiety? The answer involves a combination of factors. A systematic review of off-label antipsychotic prescribing found that quetiapine was the single most frequently prescribed off-label antipsychotic, with anxiety and insomnia topping the list of off-label uses.3Current Pharmaceutical Design. Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends
Part of the explanation is that quetiapine does have evidence for other anxiety-related conditions, and prescribers sometimes generalize from those. There is strong support for quetiapine in generalized anxiety disorder (GAD), where it has been tested in large trials and shown to reduce symptoms. There is also reasonable evidence for it as an add-on in obsessive-compulsive disorder. But for other specific anxiety disorders, the data have been described as limited.4PubMed. Influence of single-dose quetiapine on fear network activity – A pharmaco-imaging study GAD and panic disorder are different conditions with overlapping but distinct brain circuitry, and what works for one does not automatically work for the other.
Another factor is the sedating quality of quetiapine, especially at low doses. When someone is in acute distress from a panic attack, a medication that makes them feel calmer and sleepier can feel like it is “working,” even if it is not targeting the underlying panic mechanism. Doctors sometimes reach for quetiapine because benzodiazepines carry addiction risk and SSRIs take weeks to kick in, leaving a gap where patients need something. Quetiapine fills that gap pharmacologically, but filling a gap is not the same as treating the condition.
How Quetiapine Affects the Brain
Quetiapine interacts with several receptor systems, which is part of why its effects feel so broad. At higher doses used for schizophrenia or bipolar mania, it blocks dopamine D2 receptors and serotonin 5-HT2A receptors. A brain imaging study found that at 750 mg per day, quetiapine occupied about 41% of D2 receptors and 74% of 5-HT2A receptors; at 450 mg per day, those numbers dropped to about 30% and 57% respectively. At doses below 450 mg, D2 occupancy was too low to measure reliably.5PubMed. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study
This is relevant because the doses prescribed off-label for anxiety and insomnia are typically well below 450 mg, often in the 25 to 150 mg range. At those doses, quetiapine’s main pharmacological action is blocking histamine H1 receptors, which causes drowsiness. It also blocks certain adrenergic receptors. The serotonin and dopamine effects that make it an antipsychotic at higher doses are largely absent at the low doses used for sleep and anxiety. In practical terms, a low-dose quetiapine prescription for panic attacks is pharmacologically closer to a strong antihistamine than to a true antipsychotic, but it still carries the metabolic and neurological side-effect profile of an antipsychotic.
The Bipolar Exception
There is one clinical context where quetiapine has shown benefits for panic-like symptoms, and it is worth distinguishing from pure panic disorder. In people with bipolar disorder who experience comorbid anxiety, quetiapine XR has demonstrated reductions in panic-related symptoms.6Therapeutic Advances in Psychopharmacology. Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: a structured review A randomized trial comparing quetiapine XR, divalproex, and placebo in bipolar patients with significant anxiety found that quetiapine XR at a mean dose of about 186 mg per day produced rapid and sustained improvements on multiple anxiety measures, outperforming both divalproex and placebo.7PubMed. Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient
This distinction matters a lot. If you have bipolar disorder and also experience panic attacks, quetiapine may genuinely help with both the mood instability and the anxiety. It is already a standard treatment for bipolar disorder, so the anxiety benefit comes as a bonus within an indication the drug is suited for. But if you have panic disorder without bipolar disorder, this trial does not apply to you. The biological context is different: bipolar mood instability may amplify anxiety through mechanisms that quetiapine addresses, while standalone panic disorder involves a fear-circuit dysfunction that quetiapine does not appear to fix.
What Brain Imaging Shows About Fear Circuits
A neuroimaging study offers a useful window into why quetiapine might fall short for panic. Researchers gave a single dose of quetiapine to patients with a specific phobia and then scanned their brains while showing them fear-triggering images. As expected, the patients showed stronger amygdala activation to phobia-related stimuli compared to neutral ones. But quetiapine had no detectable effect on that fear-network activity. On questionnaire measures, the drug did reduce somatic anxiety symptoms like racing heart and sweating, but it did not reduce general psychological anxiety.8PubMed. Influence of single-dose quetiapine on fear network activity – A pharmaco-imaging study
This is a single study using a single dose in phobia patients rather than panic patients, so it should not be over-interpreted. But the pattern is suggestive: quetiapine may dampen the physical sensations of anxiety (the racing heart, the shaking, the sweating) through its antihistamine and adrenergic effects, while leaving the central fear circuitry untouched. For someone having a panic attack, the physical symptoms are a huge part of the distress, so reducing them can feel like the drug is working. But the cognitive fear spiral, the catastrophic thinking, and the anticipatory dread that define panic disorder may not be addressed at all.
Metabolic Side Effects at Low Doses
One of the most important things to understand about quetiapine is that the metabolic side effects do not disappear at low doses. A meta-analysis found that even low-dose quetiapine caused statistically meaningful weight gain, averaging about half a kilogram more than placebo. More concerning, patients on low-dose quetiapine were roughly twice as likely to gain 7% or more of their baseline body weight, a threshold considered clinically significant. The drug also reduced HDL cholesterol, the “good” cholesterol.9PubMed. Metabolic Adverse Effects of Low-Dose Quetiapine: A Systematic Review and Meta-Analysis
A prospective cohort study confirmed that this effect is dose-dependent, meaning higher doses produce more weight gain, but also emphasized that the metabolic risks at low doses should not be dismissed just because the effect size is smaller than at full antipsychotic doses.10Pharmacopsychiatry. Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study For someone taking 50 mg at bedtime for anxiety, the half-kilogram average may not sound alarming, but it represents an average. Some individuals gain considerably more, and the lipid changes add cardiovascular risk over time. When the clinical evidence for the anxiety indication is weak, these metabolic costs look less acceptable.
Beyond metabolic effects, the FDA and quetiapine’s manufacturer have issued warnings about QTc interval prolongation, a heart-rhythm abnormality that can in rare cases lead to a dangerous arrhythmia called torsade de pointes. A review of case reports found that the cases overwhelmingly involved additional risk factors: most patients were female, were taking other drugs that prolong QTc, had electrolyte imbalances, or had overdosed. Among patients using quetiapine appropriately and without additional risk factors, no cases of torsade de pointes or sudden cardiac death were found.11PubMed Central. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports The heart risk is low for most people, but it is one more item in a side-effect column that, for panic disorder specifically, has very little in the benefit column to balance it.
Withdrawal Is a Real Concern
Quetiapine is not classified as addictive in the way benzodiazepines are, but stopping it abruptly can produce a withdrawal syndrome that is unpleasant enough to keep people on the drug longer than they intended. A systematic review of quetiapine withdrawal found a consistent association between rapid cessation and a cluster of symptoms including nausea, vomiting, agitation, restlessness, sweating, irritability, anxiety, sleep disturbance, rapid heart rate, elevated blood pressure, and dizziness. Some cases also involved a withdrawal dyskinesia with abnormal involuntary movements, along with confusion and difficulty speaking.12Australian & New Zealand Journal of Psychiatry. Quetiapine withdrawal: A systematic review
The irony is hard to miss. A person who started quetiapine because of anxiety may find that stopping it produces rebound anxiety and insomnia that feel like a return of the original problem. This can create a cycle where each attempt to discontinue feels like proof the drug was working, when in reality the symptoms are a withdrawal effect. Gradual tapering under medical supervision reduces this risk, but many patients prescribed low-dose quetiapine off-label are not always counseled about the need for a slow taper.
What Your Doctor Should Tell You About Off-Label Prescribing
When a medication is prescribed off-label, it means the doctor is using their clinical judgment to try something that has not been specifically approved for your condition. This is legal and common in medicine, and sometimes it is the right call. But ethical practice requires that you be clearly told the drug is not approved for the condition being treated, that you understand both the potential benefits and the specific risks of that drug, and that alternative treatments have been discussed.13Biomedical and Pharmacology Journal. Trends in the Use of Antipsychotics for Off-Label Indications: Clinical and Ethical Considerations
In the case of quetiapine for panic attacks, the conversation should be unusually frank. First-line treatments for panic disorder, including SSRIs, SNRIs, and cognitive behavioral therapy, have a robust evidence base. Benzodiazepines work rapidly but carry dependence risks that make long-term use problematic. If those approaches have been tried and have failed, augmenting with quetiapine is a reasonable clinical experiment, but it should be framed as exactly that: an experiment, not a proven treatment. If your prescriber hands you a quetiapine prescription for panic without mentioning that the trial evidence is negative, without discussing SSRIs or therapy, and without explaining the metabolic and withdrawal risks, that is a conversation worth pushing back on.
When Quetiapine Might Genuinely Make Sense
Despite the weak evidence for standalone panic disorder, there are specific clinical situations where quetiapine for someone with panic attacks is a defensible choice. The clearest case is the bipolar patient with comorbid panic symptoms, where trial data do show benefit and where quetiapine may already be part of the mood-stabilizing regimen. Another scenario involves people with severe insomnia driven by nighttime panic attacks, where the sedating properties of low-dose quetiapine can break a destructive cycle of sleeplessness and daytime anxiety, buying time for an SSRI to reach its full effect. Some clinicians also turn to quetiapine when a patient cannot tolerate SSRIs due to side effects, has a history of benzodiazepine misuse that rules out that class, and needs something while waiting for therapy to take hold.
In all of these situations, the decision involves weighing the known risks of quetiapine against the costs of leaving the patient untreated. That calculus is personal and clinical, not something a guideline can resolve for everyone. But it should always be an active decision, not a reflexive one. The ease with which low-dose quetiapine is prescribed, and the assumption that “low dose means low risk,” has outpaced the evidence in a way that leaves a lot of patients taking an antipsychotic for a condition it has not been shown to treat.
How Panic Disorder Treatment Differs From General Anxiety Treatment
Part of the confusion around quetiapine and panic stems from the habit of lumping all anxiety conditions together. Generalized anxiety disorder, social anxiety, specific phobias, and panic disorder share surface-level features like worry and physical tension, but they involve partly different brain circuits and respond to partly different treatments. Quetiapine has its best evidence in GAD, where persistent background worry and restlessness are the primary features. Panic disorder, by contrast, is defined by sudden, discrete attacks that peak within minutes, often accompanied by a feeling of impending doom and intense physical symptoms. The fear circuitry involved in panic attacks is rapid, automatic, and centered on the amygdala’s threat-response system in a way that differs from the slow-burn worry of GAD.
This biological distinction helps explain why a drug can work for one anxiety condition and not another. Medications that broadly reduce arousal, like antihistamines and low-dose antipsychotics, can take the edge off the persistent tension of GAD. But they appear less effective at interrupting the rapid-fire alarm system that generates a panic attack. SSRIs work for panic disorder in part because they gradually recalibrate serotonin signaling in the fear circuits over weeks, reducing both the frequency and severity of attacks. Benzodiazepines work acutely because they enhance GABA signaling, which rapidly inhibits the amygdala’s alarm response. Quetiapine, at the low doses typically used off-label, does neither of these things particularly well. It sedates, and sedation can blunt some of the physical intensity of panic. But sedation is not treatment.